Table 1.
Demographic and clinical characteristics of the Data Bank and Biorepository cancer patient cohort from Roswell Park Comprehensive Cancer Center (n=5,807)
| Characteristic | na | Mean (SD) or % |
|---|---|---|
| Age at Diagnosis | 5,807 | 60.63 (11.99) |
| Sex | ||
| Female | 3,180 | 54.80% |
| Male | 2,627 | 45.20% |
| Race | ||
| White | 5,398 | 93.00% |
| Black | 203 | 3.50% |
| Other | 73 | 1.30% |
| Unknown | 133 | 2.30% |
| Education | ||
| <High school | 396 | 6.90% |
| High school/GED | 1,680 | 29.40% |
| Some college or tech school | 1,870 | 32.80% |
| 4-year college degree or higher | 1,763 | 30.90% |
| Pre-diagnostic RPA | ||
| Yes | 4,417 | 75.60% |
| No | 1,390 | 24.40% |
| Pre-diagnostic RPA Frequency | ||
| None | 1,390 | 24.80% |
| 1–2 days per week | 985 | 17.60% |
| 3–4 days per week | 1,912 | 34.10% |
| 5 or more days per week | 1,319 | 23.40% |
| Post-diagnostic RPA | ||
| Yes | 3,332 | 58.10% |
| No | 2,400 | 41.90% |
| Post-diagnostic RPA Frequency | ||
| None | 2,400 | 41.90% |
| 1–2 days per week | 1,301 | 22.70% |
| 3–4 days per week | 1,173 | 20.50% |
| 5 or more days per week | 858 | 15.00% |
| Habitual RPA Status | ||
| Inactive pre & post (habitual inactivity) | 1,056 | 18.70% |
| Inactive pre; active post (increased activity) | 323 | 5.70% |
| Active pre; inactive post (decreased activity) | 1,309 | 23.20% |
| Active pre & post (habitual activity) | 2,951 | 52.30% |
| Body Mass Index (kg/m2) | ||
| Underweight (BMI <18.5) | 94 | 1.60% |
| Normal Weight (BMI 18.5–24.99) | 1,539 | 26.50% |
| Overweight (BMI 25–29.99) | 1,932 | 33.30% |
| Obese (BMI ≥30) | 1,991 | 34.30% |
| Smoking Status | ||
| Never | 2,426 | 42.60% |
| Former | 2,594 | 45.50% |
| Current | 680 | 11.90% |
| Tumor Stage | ||
| Stage I | 1,723 | 29.70% |
| Stage II | 1,393 | 24.00% |
| Stage III | 1,024 | 17.60% |
| Stage IV | 979 | 16.90% |
| Unknown | 688 | 11.80% |
| Treatment Type | ||
| Surgery only | 813 | 14.00% |
| Adjuvant only | 3,768 | 64.90% |
| Adjuvant and post-adjuvant | 367 | 6.30% |
| Neoadjuvant and adjuvant | 830 | 14.30% |
| Unknown | 29 | 0.50% |
| Disease Site | ||
| Bladder | 123 | 2.10% |
| Brain | 18 | 0.30% |
| Breast | 1,232 | 21.20% |
| Cervical | 48 | 0.80% |
| Colorectal | 345 | 5.90% |
| Esophageal | 173 | 3.00% |
| Head and neck | 74 | 1.30% |
| Hematological | 486 | 8.40% |
| Kidney | 342 | 5.90% |
| Liver | 107 | 1.80% |
| Lower GI | 72 | 1.20% |
| Lung | 555 | 9.60% |
| Other | 156 | 2.70% |
| Other Gynecological | 45 | 0.80% |
| Ovarian | 151 | 2.60% |
| Pancreas | 127 | 2.20% |
| Prostate | 833 | 14.30% |
| Sarcoma | 84 | 1.40% |
| Skin (95% Melanomas) | 347 | 6.00% |
| Stomach | 107 | 1.80% |
| Testicular | 9 | 0.20% |
| Thyroid | 57 | 1.00% |
| Endometrial | 316 | 5.40% |
| Follow-up Duration (Months) | 5,807 | 59.06 (0.56) |
| All-cause Mortality | ||
| Alive | 3,851 | 66.30% |
| Deceased | 1,956 | 33.70% |
| Cancer-Specific Mortality | ||
| Alive | 3,851 | 66.30% |
| Deceased from cancer | 1,570 | 27.00% |
| Deceased from non-cancer cause | 229 | 3.90% |
| Deceased from unknown cause | 157 | 2.70% |
a
Columns may not sum to total due to missing data